JPRN-UMIN000013539已完成未知
Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients - Efficacy and Safety of SGLT-2 inhibitor to break loose from glucose toxicity and to withdraw insulin therapy in type 2 diabetic inpatients
Shiga University of Medical Science Department of Internal Medicine Division of Diabetology, Nephrology, Neurology0 个研究点目标入组 20 人开始时间: 2014年3月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.age <20, >=75 2.BMI <22 kg/m2 3.eGFR <45 ml/min/1.73m2 4. anti-GAD antibody titer >=10 or insulin-dependent 5. patients who have anemia (Hb male <12 g/dl, female <11 g/dl) 6. patients who have cancer, or infection 7. patients judged to be disqualified to this research by physicians
研究者
相似试验
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50
招募中
4 期
Efficacy of SGLT2 inhibitor for Non-Alcoholic Fatty Liver Diseaseon Alcoholic Fatty Liver DiseaseC06.552.241.519C18.452.394.750.149ObesityType 2 Diabetes MellitusRBR-48rxwbCentro Educacional Hyarte
已完成
不适用
ong-term efficacy and safety of the SGLT2 inhibitors in Japanese patients with type 2 diabetes mellitus.JPRN-UMIN000037872akakinen Clinic630
已完成
不适用
Efficacy and safety in SGLT2 inhibitor for non-diabetes complicated by non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.JPRN-UMIN000031041Kobe university school of medicine, Diabetes and Endocrinoplogy30
已完成
不适用
The efficacy of the administration of SGLT-2 inhibitor and/or DPP-4 inhibitor in type 2 diabetic patient with basal-bolus insulin therapy.JPRN-UMIN000020742Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School60